Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Neurology Module

Program Description

Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

This activity focuses on the role of neurology clinicians including when to raise clinical suspicion of ARIA in the clinic, how to evaluate suspected ARIA, and what courses of action may be needed to treat/manage ARIA should it occur.

Note that the core activity is supplemented by an interactive clinical summary designed specifically for neurology clinicians. This convenient, mobile-friendly tool was developed to assist clinicians in considering how best to implement ARIA guidelines into their own day-to-day practice.

Target Audience

This activity is intended for neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and management of patients with AD neurobiology.

Learning Objectives

Upon completion of the educational activity, participants should be able to:
  • Outline optimal proactive and individualized monitoring strategies (e.g., baseline and follow-up MRIs) for ARIA in all patients prescribed amyloid-targeting DMT to ensure it is identified and managed in a timely manner
  • Identify both proactive and reactive management strategies that have been employed for individual presentations of ARIA, including optimal patient selection for these approaches, to maximize patient safety while minimizing the need for therapeutic adjustment

Check Out These Other ARIA Modules 

Course summary
Available credit: 
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Course opens: 
Course expires: 
   James Galvin, MD, MPH, FANA (Chair)
   Director, Comprehensive Program for Brain Health
   Professor, Department of Neurology
   University of Miami Miller School of Medicine
   Miami, FL


   Jon Toledo, MD, PhD
   Cognitive Neurology, Nantz National Alzheimer’s Center
   Houston Methodist Hospital
   Houston, TX

This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.


Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Education Resources has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.  This activity is designated for 0.5 AAPA Category 1 CME Credits.  Physician Assistants should only claim credit commensurate with the extent of their participation.
A Certificate of Participation will be given upon completion of the activity enabling participants to register their credit with the appropriate licensing boards or associations.

Disclosure of Financial Relationships

Medical Education Resources (MER) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All relevant financial relationships have been mitigated by MER. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure

Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.

Faculty Disclosure

Dr Galvin reported the following financial relationships:

  • Consulting Fees: Alpha Cognition, Biogen, Cognivue, Eisai, Eli Lilly, Genentech/Roche, Otsuka

Dr Toledo has no financial relationships to disclose.

Disclosure of Unlabeled Use/Disclaimer

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Commercial Support

This continuing education activity is supported by educational grants from Lilly.

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period July 14, 2023 through July 14, 2024, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.



Available Credit

  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance


Please login or register to take this course.